25.08.2016 Views

VACCINE

4Xcr4V9hT

4Xcr4V9hT

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

“Because the product is itself a virus,<br />

traditional viral clearance steps are generally not included in the manufacturing process ...”<br />

PDA Journal Of Pharmaceutical Science And Technology • November 2011<br />

Application of Risk Assessments<br />

in the Design of the Overall Viral Control Strategy Used<br />

during the Manufacture and Testing of Live Virus Vaccines<br />

Author information<br />

Pennathur S.<br />

MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878<br />

Abstract<br />

CONFERENCE PROCEEDING<br />

Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in<br />

Bethesda, MD, USA; December 1-3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda,<br />

MD) and Michael Wiebe (San Francisco, CA) It is important to include a risk assessment process in the overall<br />

viral control strategy used during the manufacture and testing of live virus vaccines. Because the product is itself<br />

a virus, traditional viral clearance steps are generally not included in the manufacturing process, and there is<br />

normally no inactivation step in the manufacturing process either. The risk assessment is therefore necessary to<br />

identify potential sources for entry of adventitious agents into the vaccine, and to develop a strategy to minimize<br />

or eliminate the sources through which adventitious agents can enter the vaccine. The risk assessment can also be<br />

used to tailor the biosafety testing that is performed on raw materials, vaccine seeds, vaccine bulk materials, and<br />

final product. Biosafety testing is normally designed to ensure the detection of both known and unknown adventitious<br />

agents, but the results of the risk assessment can be used to put in place a biosafety testing strategy designed<br />

to maximize the detection of an adventitious agent that is potentially likely to be present in the vaccine. The risk<br />

assessment therefore enables the development of a comprehensive viral control strategy and provides a higher<br />

level of assurance that the vaccine will be free from contamination by adventitious agents.<br />

http://www.ncbi.nlm.nih.gov/pubmed/22294607

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!